Patients taking Tysabri report improvement in physical and psychological well-being over time Sep 12, 2009
Dsseldorf, Germany Sept. 11, 2009 Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI (natalizumab) experienced an improvement in both their physical function and psychological well-being ... Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives... (EurekAlert!)
FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia Aug 1, 2009
NanoCrystal(R) Technology is a registered trademark of Elan Pharma International Limited, Ireland, a subsidiary of Elan Corporation plc (NYSE: ). The NanoCrystal(R) Technology is a proven, robust, drug optimization technology, enabling solubility for many poorly water-soluble compounds. (PR Newswire)
New outcomes study reports TYSABRI patients show overall improvement in cognition and quality of life, with lower levels of fatigue Apr 30, 2009
- April 29, 2009 - Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced results from an ongoing, one-year longitudinal health outcomes study (n=1275) in which patients who received three infusions of TYSABRI (natalizumab) reported reduced fatigue, as well significant improvements in general and disease-specific measurements of quality of life (QoL) and cognitive function ... Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a... (EurekAlert!)
New Test Predicts Whether Mild Cognitive Impairment Will Convert To Alzheimer's Disease Mar 17, 2009
Private sector support comes from pharmaceutical companies and other organizations through the Foundation for NIH, which has raised more than 25 million from both corporations and non-profits toward ADNI. Current private sector funders include Abbott Laboratories, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, General Electric Healthcare, GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly and Co., Inc.,... (Science Daily)
Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium Mar 7, 2009
March 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: ), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Elan Corporation, Plc on outstanding patent litigation related to Watson's generic version of Naprelan(R) (naproxen sodium) tablets ... Naprelan(R) is a registered trademark of Elan Corporation, Plc. (PR Newswire)
Merrion Completes Patient Enrolment in Phase IIb Study -- Results Will be Announced in Q2 2009 Feb 10, 2009
Merrion was established in 2004 to commercialise various technologies acquired from Elan Corporation, plc. Merrion's patented drug delivery technologies increase bioavailability, by improving absorption in the gastrointestinal tract, of drugs that are otherwise poorly absorbed. (Primezone Releases)
